Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Achieve Life Sciences Inc
ACHV | US
5.03
USD-0.27
-5.09%
ACHV | US
Loading StockChartView...
About Achieve Life Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
5.03
Open
5.30
High
5.30
Low
5.03
Achieve Life Sciences Inc. a clinical-stage pharmaceutical company develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada the United States and the United Kingdom. The company offers cytisinicline a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences Inc. is based in Vancouver Canada.
View LessACHV | US
Risk
88.7
Sharpe
0.35
Luna's Score
46/100
Recommendation
Hold
Luna says (ACHV | US)
What's Working
Positive Momentum
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
80.3%1 month
88.7%3 months
119.7%6 months
94.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.10
Debt to equity
0.42
Debt to assets
0.27
Ent. to EBITDA
-2.42
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-25.14M
MarketCap
172.74M
MarketCap(USD)
172.74M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-105.95
Short ratio
31.50
Short perc.
12.01
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.10
Range1M
1.83
Range3M
3.53
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.62
Price X volume
4.30M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.42 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.10 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 119.69 | 72.80 | Riskier |
| Debt to Equity | 0.42 | -1.23 | Expensive |
| Debt to Assets | 0.27 | 0.25 | Par |
| Market Cap | 172.74M | 3.66B | Emerging |
